drugset / Trial / NCT01202695

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

NCT01202695 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

Primary: • To compare the safety profile of a single intravenous administration of AVP-21D9 as compared with Placebo Secondary: * To evaluate the pharmacokinetics (PK) of a single intravenous administration of AVP-21D9 * To evaluate the immunogenicity of AVP-21D9

Timeline

Start
2010-08
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AVP-21D9 Monoclonal antibody — Intravenous

Indications